

**Minutes of the Lancashire Medicines Management Group Meeting  
Held on Thursday 9<sup>th</sup> April 2015 at Preston Business Centre**

**PRESENT:**

|                          |   |  |
|--------------------------|---|--|
| Dr Tony Naughton (TN)    | Chair of LMMG   | Lancashire CCG Network                                     |
| Christine Woffindin (CW) | Medicines Information Manager   | East Lancashire Hospitals NHS Trust                        |
| Julie Kenyon (JK)        | Senior Operating Officer Primary Care, Community & Medicines          | NHS Blackburn with Darwen CCG                              |
| Melanie Preston (MP)     | Assistant Director - Medicines Optimisation                           | NHS Blackpool CCG  |
| Kenny Li (KL)            | Senior Manager – Medicines Optimisation                               | NHS Lancashire North CCG                                   |
| Dr Kamlesh Sidhu (KS)    | GP Prescribing Lead   | NHS Lancashire North CCG                                   |
| Nicola Baxter (NB)       | Head of Medicines Optimisation  | NHS West Lancashire CCG                                    |
| Pauline Bourne (PB)      | Senior Pharmacist, Medicines Management, Deputy Chief Pharmacist      | University Hospitals of Morecambe Bay NHS Foundation Trust |
| Julie Lonsdale (JL)      | Head of Medicines Optimisation Lead Medicines Optimisation Pharmacist | NHS Fylde and Wyre CCG                                     |
| Nicola Schaffel (NS)     | Pharmacist  | NHS Greater Preston CCG, NHS Chorley and South Ribble CCG  |

**IN ATTENDANCE:**

|                          |   |                                 |
|--------------------------|---|---------------------------------|
| Elaine Johnstone (EJ)    | Service Director                              | NHS Midlands and Lancashire CSU |
| Brent Horrell (BH)       | Head of Medicines Commissioning               | NHS Midlands and Lancashire CSU |
| Susan McKernan (SM)      | Senior Medicines Performance Pharmacist       | NHS Midlands and Lancashire CSU |
| Jonathan Horgan (JH)     | Head of Medicines Management and IFR Services | NHS Midlands and Lancashire CSU |
| Jane Johnstone (Minutes) | Medicines Management Administrator            | NHS Midlands and Lancashire CSU |

| ITEM     | SUMMARY OF DISCUSSION   | ACTION |
|----------|---|--------|
| 2015/065 | <p><b>Welcome &amp; apologies for absence</b></p> <p>The Chair welcomed everyone to the meeting. Apologies for absence were received on behalf of Dr David Shakespeare, Alastair Gibson, Dr Lisa Rogan, Dr Emile Li Kam Wa, David Jones, Dr Catherine Fewster, Clare Moss and Cassandra Edgar.</p> <p>It was noted that Nicola Schaffel was attending on behalf of Clare Moss.</p> <p>The Chair introduced Jonathan Horgan, Head of Medicines Management and IFR Services from M&amp;LCSU who was in attendance to observe the meeting following his appointment into this role. Introductions took place.</p> <p>The Chair also thanked KS for chairing the March LMMG meeting in his absence.</p> |        |

| ITEM                         | SUMMARY OF DISCUSSION  | ACTION |
|------------------------------|--|--------|
| 2015/066                     | <p><b>Declaration of any other urgent business</b><br/>None.</p>   |        |
| 2015/067                     | <p><b>Declarations of interest pertinent to agenda</b><br/>None.</p>   |        |
| 2015/068                     | <p><b>Minutes of the last meeting (12<sup>th</sup> March 2015)</b><br/><br/>The minutes of the meeting dated 12<sup>th</sup> March 2015 were agreed as a true and accurate record.</p>   |        |
| 2015/069                     | <p><b>Matters arising (not on the agenda)</b><br/><br/>There were no matters arising.</p>  |        |
| <b>NEW MEDICINES REVIEWS</b> |  |        |
| 2015/070                     | <p><b>Insulin degludec plus liraglutide (Xultophy®▼)</b></p> <p>BH presented the paper, summarising the evidence review and the draft recommendation which had been consulted on, as follows:-</p> <p>The combination product insulin degludec plus liraglutide (Xultophy®▼) is not recommended to treat type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone, or combined with basal insulin, do not adequately provide glycaemic control.</p> <p>6 of 8 CCGs, 3 of 4 Acute Trusts and LCFT responded by the closing date. All 6 CCGs agreed with the recommendation. 2 Acute Trusts disagreed with the recommendation, 1 acute trust stated that some clinicians agreed and some disagreed with the recommendation and LCFT stated that they support the decision made by acute trusts within the localities.</p> <p>BH informed the group that further information had been provided by the manufacturer after the close of the consultation period. This information summarised the Dual V trial which has been completed but not fully published. This information was considered by LMMG alongside the evidence review and consultation responses.</p> <p><b>Decision</b><br/>LMMG members supported the draft recommendation.</p> |        |

| ITEM    | SUMMARY OF DISCUSSION  | ACTION   |
|---------|--|--|
|         | <p><b>Action</b><br/>The website will be updated to show Black colour classification.</p>  | <b>JJ</b>  |
| 2015/71 | <p><b>Horizon Scanning Quarter 1 2015-2016</b></p> <p>BH discussed the medicines in the Horizon Scanning paper for Quarter 1 of 2015/16.</p> <p>The following drugs were discussed and agreed by the LMMG:-</p> <p><u>The following drugs are awaiting NICE guidance; a review will not be carried out at this stage.</u></p> <p>Dexamethasone intravitreal implant – Diabetic Macular Oedema.<br/> Collagenase clostridium histolyticum – Dupuytren’s contracture.<br/> Ustekinumab – Active Psoriatic Arthritis – awaiting NICE guidance.<br/> Vedolizumab – Moderate to severe active Crohn’s disease in people who are intolerant of, not responsive to or resistant to either conventional therapy or a tumour necrosis factor antagonist.<br/> Aflibercept – Diabetic Macular Oedema.<br/> Apixaban – Treatment and secondary prevention of deep vein thrombosis and /or pulmonary embolism.<br/> Vorapaxar – atherothrombotic events in patients with a history of MI.<br/> Ciclosporin – Moderate to severe Keratoconjunctivitis sicca (or dry eye disease).<br/> Naloxegol – Opioid induced constipation in adults.<br/> Vortioxetine – Depression.<br/> Apremilast – Psoriatic arthritis following DMARDS or anti-TNFs.<br/> Apremilast – Psoriasis moderate to severe.<br/> Secukinumab – Moderate to severe plaque psoriasis in adults – first line.</p> <p><u>The following two drugs will not be put on the work plan – Acute Trusts to discuss these with Microbiology to understand if there is a desire to use these medicines and if it is likely that this use will cross into primary care.</u></p> <p>Dalbavancin – Skin and soft tissue bacterial infections.<br/> Tedizolid phosphate – Acute bacterial skin and skin structure infections.</p> <p><u>The following drugs will be put on the work plan.</u></p> <p>Insulin Glargine U300 – Type 1 and 2 diabetes mellitus.<br/> Oxycodone + Naloxone - Restless legs syndrome (severe second-line after failure of dopaminergic therapy) – this will be added to the website as Grey colour classification and for consideration if the combination products statement applies.</p> | <p style="text-align: center;"><b>Acute Trust Leads</b></p> <p style="text-align: center;"><b>JJ</b></p> |

| ITEM     | SUMMARY OF DISCUSSION  | ACTION  |
|----------|--|---|
|          | <p><u>The following drugs have previously been added to the work plan and are awaiting licence and launch</u><br/> Safinamide - Parkinson's disease (early)<br/> Bazedoxifene + conjugate oestrogens – Menopausal symptoms.<br/> Dulaglutide – Type 2 diabetes mellitus.<br/> Insulin degludec + insulin aspart – Type 2 diabetes mellitus.</p> <p><u>No action will be taken with the following drug</u><br/> Exenatide – Type 2 diabetes mellitus in adults – powder and solvent in a dual chamber pen.</p> <p><u>This drug will be discussed at the May meeting</u><br/> Infliximab biosimilar – Rheumatoid arthritis &amp; psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's disease &amp; ulcerative colitis.</p>   |   |
| 2015/072 | <p><b>LMMG – New Medicine Review Work Plan update</b></p> <p>BH discussed this paper; updating LMMG on the current status of the work plan, as follows:-</p> <p><u>Medicines for discussion at April LMMG</u><br/> Colistimethate/Colomycin – Treatment by inhalation of pseudomonas aeruginosa lung infection in patients without cystic fibrosis – a completed application form has now been received. LMMG decided that an evidence review of this product will now be undertaken.</p> <p><u>Medications for recommendation from the May LMMG</u><br/> Testosterone – Female sexual dysfunction following post oophorectomy or primary ovarian failure.</p> <p><u>Medications for recommendation from the June LMMG</u><br/> Peristeen – Faecal incontinence and constipation.<br/> Co-trimoxazole – Sub acute Bacterial Peritonitis Prophylaxis.</p> <p><u>Medications for future review</u><br/> Renavit/Ketovit – Patients on haemodialysis.<br/> LABA/LAMA combinations - COPD.</p> <p>BH informed the group that clarity is being sought from NHS England around the commissioning position for the new product Afamelanotide. Further information will be fed back once the position has been determined.</p> | <p style="text-align: center;">BH</p> <p style="text-align: center;">BH</p> |

| ITEM                                       | SUMMARY OF DISCUSSION  | ACTION                     |
|--|--|----------------------------|
| <b>GUIDELINES and INFORMATION LEAFLETS</b> |  |                            |
| <b>2015/073</b>                            | <p><b>Ivabradine</b></p> <p>SM discussed the amendments made to the Ivabradine information sheet which was updated following recent safety advice published by the Medicines and Healthcare Regulatory Agency in December 2014.</p> <p><b>Decision</b><br/>The Ivabradine information sheet was approved by LMMG.</p> <p><b>Action</b><br/>This will be uploaded to the website.</p>   | <b>JJ</b>                  |
| <b>2015/074</b>                            | <p><b>Botulinum Toxin</b></p> <p>SM discussed the local commissioning positions, prescribing data and the formulations of botulinum toxin which were included in the scoping paper.</p> <p><b>Decision</b><br/>LMMG decided that the paper will be used for discussions in local health economies.</p> <p><b>Action</b><br/>SM to clarify commissioning responsibility for botulinum toxin in Multiple Sclerosis (MS) with NHS England. Upon receipt of this information the website will be updated.</p> <p>To avoid confusion, the LMMG Recommendation column will be removed from the table – High Cost Drugs CCG funding positions (hosted on the LMMG website).</p> | <b>SM</b><br><br><b>SM</b> |
| <b>2015/075</b>                            | <p><b>LMMG – Guidelines Work Plan update</b></p> <p>JL discussed this paper, updating LMMG on the current status of the work plan, as follows:-</p> <p><u><i>Due for approval at the May LMMG; currently out to consultation</i></u><br/>Non cancer pain guidelines.<br/>Gout prescribing guidance scope.<br/>Secondary prevention of stroke post TIA scope.</p> <p><u><i>Due for approval at the June meeting</i></u><br/>Treatment of Juvenile Idiopathic Arthritis – this is due to go out to consultation in April.<br/>Erectile Dysfunction – this is due to go out to consultation in April.</p>   |                            |

| ITEM   | SUMMARY OF DISCUSSION  | ACTION  |
|--|--|---|
|  | <p><u>Due for approval at the July meeting</u><br/>ADHD shared care guideline for children – this is currently in development.</p> <p><u>Ongoing work</u><br/>Apomorphine shared care guidelines – awaiting LTHT to send their completed document for comments and/or approval at LMMG.</p> <p>Gout Prescribing guideline – the development of this will commence following completion of the scoping exercise.</p> <p>Secondary prevention of stroke post TIA – the development of this will commence following completion of the scoping exercise.</p> <p>Neuropathic pain guideline – as part of the non-cancer pain guideline review, it has been queried if these guidelines are still required as current NICE guidance is available.</p>  |   |
| <b>NATIONAL DECISIONS FOR IMPLEMENTATION</b> |  |   |
| <b>2015/076</b>                              | <p><b>New NICE Technology Appraisal Guidance for Medicines (March 2015)</b></p> <p>TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome -Due to the potential cost impact across Lancashire, SM will contact Cardiologists from Secondary Care and Tertiary Care (Blackpool) to understand the potential use in these centres. LMMG agreed that this will be put on the website as Amber 0 colour classification.</p> <p>TA336 Empagliflozin in combination therapy for treating type 2 diabetes – LMMG agreed that this will be put on the website at Green colour classification.</p> <p>TA337 Rifaximin for preventing episodes of overt hepatic encephalopathy - LMMG agreed that this will be put on the website as Amber 0 colour classification.</p> <p>TA338 Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib - LMMG agreed that this will be put on the website as Black Colour Classification.</p> | <p><b>SM</b></p> <p><b>All website actions<br/>JJ</b></p> |
| <b>2015/077</b>                              | <p><b>New NHS England medicines commissioning policies (March 2015)</b></p> <p>SM discussed this paper which was brought to the meeting for information only. NHS England has launched a 30 day open consultation on 33 clinical commissioning policies, as well as 5</p>  |   |

| ITEM                   | SUMMARY OF DISCUSSION  | ACTION                              |
|------------------------|--|-------------------------------------|
|                        | <p>service specifications and 2 other commissioning products. The consultation period closes on 23<sup>rd</sup> April 2015.</p> <p><b>Action</b><br/>CCGs and Acute Trusts to respond to the consultation as appropriate.</p>  | <p><b>CCGs and Acute Trusts</b></p> |
| <p><b>2015/078</b></p> | <p><b>Evidence reviews published by SMC or AWMSG</b></p> <p>BH discussed the SMC and AWMSG guidance for medicines published in March 2015.</p> <p><u>The following medicines will be brought to the May LMMG meeting for discussion.</u></p> <p>SMC ID number 007/14 Infliximab (Inflectra) - Infliximab (Inflectra®) is accepted for restricted use within NHS Scotland.</p> <p>SMC ID number 1006/14 infliximab (Remsima) - Infliximab (Remsima®) is accepted for restricted use within NHS Scotland.</p> <p>AWMSG Ref number 2253/Infliximab (Inflectra®) is recommended as an option for restricted use within NHS Wales.</p> <p>AWMSG Ref number 2254/Infliximab (Remsima®) is recommended as an option for restricted use within NHS Wales.</p> <p><u>No action is required with the following drug; a submission / review is awaited from LCFT</u></p> <p>AWMSG Ref number 1142/lurasidone (Latuda®) - Lurasidone (Latuda®) is recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults aged 18 years and over – LCFT are in the process of drafting a paper. No further action is required at this stage.</p> <p><u>The following drug has previously been prioritised for review</u></p> <p>AWMSG Ref number 10038/Umeclidinium/vilanterol (Anoro® Ellipta®)</p> <p>It was agreed that the remaining SMC/AWMSG recommendations in the paper did not meet LMMG criteria; therefore LMMG agreed that no further action would be taken with regards to them.</p> |                                     |

| ITEM                         | SUMMARY OF DISCUSSION   | ACTION  |
|------------------------------|---|---|
| <b>OTHER PROPOSALS</b>       |   |   |
| 2015/079                     | <p><b>LMMG Annual Report 2014-15</b></p> <p>EJ presented the annual report which gave an overview of the LMMG's activity in the 2014-15 financial year.</p> <p>EJ commended the work that LMMG members have undertaken in the last financial year, in particular the work undertaken to further refine and improve processes.</p> <p>CCG leads were asked to provide any further decisions made on the medicines listed in the LMMG recommendations and CCG decisions table (Appendix 6) by the end of April 2015. TN will then take the updated annual report to the CCG Network May meeting.</p> <p><b>Action:</b><br/>CCG Leads to provide any further decisions made on the medicines listed in the LMMG recommendations and CCG decisions table by the end of April 2015.</p>  | <b>CCG Leads</b>  |
| 2015/080                     | <p><b>Observers at LMMG meetings</b></p> <p>TN made a proposal that newly appointed staff, consultants or pharmacists within constituent organisations may attend LMMG as observers to the meeting to provide development opportunities. LMMG discussed this proposal and decided upon the following:-</p> <p><b>Decision</b><br/>It was agreed that observers from constituent organisations would be allowed to attend. It was further agreed that no more than two observers will be in attendance at any one LMMG monthly meeting.</p> <p>Any member organisations wishing for an observer to attend, should email the <a href="mailto:medicinesmanagement@lancashirecsu.nhs.uk">medicinesmanagement@lancashirecsu.nhs.uk</a> email address with their details before the closing date for submission of agenda items each month. Places will be assigned on a first come, first served basis.</p> <p>LMMG members will be notified in advance (via the agenda) of the details of any observers who will be attending the next meeting.</p> | <b>LMMG members to email with the details of any observers they wish to attend an LMMG meeting.</b> |
| <b>ITEMS FOR INFORMATION</b> |   |   |
| 2015/081                     | <b>Minutes of the Lancashire Care FT Drugs and Therapeutics Committee (17<sup>th</sup> March 2015)</b>  |   |



| ITEM     | SUMMARY OF DISCUSSION   | ACTION |
|----------|---|--------|
|          | The group noted these minutes.  |        |
| 2015/082 | <p><b>Minutes of the Lancashire CCG Network (26<sup>th</sup> February 2015)</b></p> <p>The group noted these minutes.</p>   |        |
| 2015/066 | <p><b>Elaine's last LMMG meeting</b></p> <p>TN highlighted to LMMG members that this would be Elaine's last LMMG meeting as she was moving to a new role in the CSU. TN wished to highlight the integral part that Elaine had played in the development and strategic direction of LMMG, enabling the group to function effectively and collaboratively across Lancashire. TN also thanked Elaine for her invaluable support to his role as chair of the group. The group commended Elaine for all of her input and wished her well in her new role.</p> <p>EJ thanked TN for his kind comments. She said she had very much enjoyed being part of the development of LMMG, and thanked all members for their commitment to its development and continuous improvement. She looked forward to continuing to hear of its activities and wished the group every success in the future.</p> |        |

**Date and time of the next meeting**

Thursday 14<sup>th</sup> May 2015, 9.30 am to 11.30 am, Meeting Room 253, Preston Business Centre

**ACTION SHEET FROM THE  
LANCASHIRE MEDICINES MANAGEMENT GROUP  
9<sup>th</sup> April 2015**

| MINUTE NUMBER  | DESCRIPTION  | ACTION | DATE       | STATUS AT 08.05.15 |
|--|--|--------|------------|--------------------|
| <b>ACTION SHEET FROM THE 12<sup>th</sup> FEBRUARY 2015 MEETING</b> |  |        |            |                    |
| 2015/027   | <p><b>RAG list review – immunosuppressants post renal transplant.</b></p> <p><b>Update:</b> JL has contacted Specialised Commissioning/NHS England; there are ongoing discussions with LTH, however the timescales for the repatriation plan have not been determined at this time. LTH to inform LMMG of timescales once agreed.</p>  | DJ     | 07.05.2015 | Open               |
| 2015/031   | <p><b>Horizon Scanning 2015/16</b></p> <p><b>Action:</b> LMMG members to consult internally with Specialists discussing the prioritisation for new medicines reviews for the 2015/16 financial year.</p> <p><b>Update:</b> BH has received feedback from 2 CCGs, LCFT and 1 Acute Trust. No further information has been received since the last meeting. BH will send a reminder email and bring a summary of drugs which have been prioritised to the next meeting.</p>  | BH     | 09.04.15   | Closed             |
| 2015/037   | <p><b>Rheumatology Alliance – Update</b></p> <p><b>Action:</b> TN to update LMMG once formal feedback has been received from the rheumatology alliance meeting</p> <p><b>Update:</b> Discussions are ongoing; TN will update the LMMG upon receipt of feedback from the Rheumatology Alliance.</p>   | TN     | 07.05.2015 | Closed             |
| 2015/045   | <p><b>Minutes of the Lancashire Care FT Drugs and Therapeutics Committee (20.01.2015)</b></p> <p><b>DT/08/15 NHS England Misuse of Pregabalin and Gabapentin</b></p> <p><b>Action:</b> CF will forward the NHS England document to the CSU Medicines Management Team for forwarding to CCGs.</p> <p><b>Update:</b> NHS England has been working on their Pain Guidelines for Prisons on the use of Pregabalin and Gabapentin. CF has forwarded both documents to the CSU; they have been circulated to the LMMG.</p> | CF     | 09.04.15   | Closed             |

|   |  |                   |          |        |
|---|--|-------------------|----------|--------|
| 2015/046                                      | <p><b>Ticagrelor</b><br/> <b>Action:</b> In light of recent requests for the use of Ticagrelor for a period longer than 12 months – CCG Medicines Management leads to carry out an audit of Ticagrelor prescribing in Primary Care.<br/> <b>Update:</b> BH will send a reminder email to the CCG MM Leads; a summary will be brought back to the May LMMG meeting as an agenda item.</p>   | CCG MM Leads      | 07.05.15 | Open   |
| <b>ACTION SHEET FROM THE 12 MARCH MEETING</b> |  |                   |          |        |
| 2015/051                                      | <p><b>Olodaterol in the treatment of COPD</b></p> <p>LR will share the existing East Lancs Respiratory pathway with CCG MM Leads.<br/> <b>Update:</b> JL will check if this has been received; a reminder email will be sent to LR.</p> <p>CE to coordinate a meeting to agree the scope and timescales for the inhaler review. An update will be provided at the next meeting.<br/> <b>Update:</b> A compatible date has not been arrange yet due to the Easter period; CE is currently looking at further dates.</p>   | LR                | 07.05.15 | Closed |
|   |  | CE                | 07.05.15 | Closed |
| 2015/052                                      | <p><b>LMMG – New Medicine Reviews Work Plan update</b></p> <p>Infliximab Biosimilar - MP will forward an email trail regarding the North West Contract to the CSU for cascading. Infliximab Biosimilar will be added as an agenda item for the May LMMG meeting.<br/> <b>Update:</b> MPs email has been circulated. BH will bring a summary of information received from Lorraine Booth to the May LMMG meeting.</p> <p>Liothyronine - Acute Trusts to provide the contact details of appropriate specialists; the CSU will then contact specialists to see if there is a requirement for its use and in which indications. A review of Liothyronine will be carried out dependent upon the feedback from the Specialists.<br/> <b>Update:</b> Contacts have been received from some, but not all trusts. BH will send a reminder email.</p> <p>Botox – Individual Funding Request<br/> CSU will look at the evidence base and the commissioning policy position for the requested indication.<br/> <b>Update:</b> This will be picked up outside of</p> | MP                | 09.04.15 | Closed |
|   |  | BH                | 07.05.15 | Open   |
|   |  | Acute Trust Leads | 07.05.15 | Open   |
|   |  | BH                | 07.05.15 | Open   |
|   |  | BH                | 09.04.15 | Closed |

|          |  |           |                               |        |
|----------|--|-----------|-------------------------------|--------|
|          | <p>LMMG through the IFR process.</p> <p>A financial analysis on current costs by CCG will be undertaken.<br/> <b>Update:</b> This is discussed under the Botox agenda item 2015/074.</p> <p>SM will liaise with NWCSU, Manchester regarding details of their approach to this issue<br/> <b>Update:</b> This is discussed under the Botox agenda item 2015/074.</p>        | JL        | 09.04.15                      | Closed |
|          | <p>SM will liaise with NWCSU, Manchester regarding details of their approach to this issue<br/> <b>Update:</b> This is discussed under the Botox agenda item 2015/074.</p>   | SM        | 09.04.15                      | Closed |
| 2015/053 | <p><b>Aripiprazole Long Acting Injection</b></p> <p>CF will forward the LCFT and the SMC/AWMSG evidence reviews to CSU.</p> <p>CSU will send this out to consultation once the reviews have been considered and an appropriate consultation document / evidence review developed.<br/> <b>Update:</b> this has been added to the work plan; BH will liaise with NETAG.</p> | CF        | 09.04.15                      | Closed |
|          |  | BH        | In line with agreed work plan | Open   |
| 2015/054 | <p><b>Drugs for Dementia</b></p> <p>SM will liaise with LCFT regarding the rebranding of the Shared Care Guideline to an information sheet; this will then be circulated for comments.<br/> <b>Update:</b> this work has been started and is ongoing.</p>  | SM        | 09.04.15                      | Closed |
| 2015/055 | <p><b>RAG list Annual Review – List 2</b></p> <p>Darifenacin for Urinary frequency, urgency and incontinence – KL will forward the LNCCG pathway to CCG Leads.<br/> <b>Update:</b> This has been sent.</p>   | KL        | 09.04.15                      | Closed |
| 2015/057 | <p><b>Joint Palliative Care Guideline</b></p> <p>The CSU will send the current document out to LMMG members and a joint LMMG response will be submitted.<br/> <b>Update:</b> this has been circulated, one response has been received. SM will re-circulate the document.</p>  | SM        | 09.04.15                      | Closed |
| 2015/061 | <p><b>Rebate Scheme Assessment Process</b></p> <p>Decision making group - CCG Leads will discuss further requirements outside of this meeting.<br/> <b>Update:</b> Close item; this is being discussed outside of the LMMG meeting.</p>  | CCG Leads | 09.04.15                      | Closed |

| <b>ACTION SHEET FROM THE 9<sup>th</sup> APRIL 2015 MEETING</b> |   |                              |                 |               |
|--|---|------------------------------|-----------------|---------------|
| <b>2015/71</b>   | <p><b>Horizon Scanning Quarter 1 2015-16</b><br/>Dalbavancin – Skin and soft tissue bacterial infections.<br/>Tedizolid phosphate – Acute bacterial skin and skin structure infections<br/><b>Action:</b> Acute Trust Leads to discuss these with Microbiology to see if there is a requirement for their use.</p>                | <b>Acute Trust Leads</b>     | <b>07.05.15</b> | <b>Open</b>   |
| <b>2015/072</b>  | <p><b>LMMG – New Medicine Review Work Plan update</b><br/><br/>Clarity is being sought from NHS England around the commissioning position for the new product Afamelanotide. Further information will be fed back once the position has been determined.</p>  | <b>BH</b>                    | <b>07.05.15</b> | <b>Close</b>  |
| <b>2015/076</b>  | <p><b>New NICE Technology Appraisal Guidance for Medicines (March 2015)</b><br/><br/>TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome<br/><b>Action:</b> Cardiologists from Secondary Care and Tertiary Care (Blackpool) to understand the potential use in these centres.</p> | <b>SM</b>                    | <b>07.05.15</b> | <b>Open</b>   |
| <b>2015/077</b>  | <p><b>New NHS England medicines commissioning policies (March 2015)</b><br/><br/>CCGs and Acute Trusts to respond to the consultation as appropriate.</p>   | <b>CCGs and Acute Trusts</b> | <b>23.04.15</b> | <b>Closed</b> |
| <b>2015/079</b>  | <p><b>LMMG Annual Report 2014-15</b><br/><br/><b>Action:</b> CCG Leads to provide any further decisions made on the medicines listed in the LMMG recommendations and CCG decisions table by the end of April 2015.</p>  | <b>CCG Leads</b>             | <b>07.05.15</b> | <b>Open</b>   |